ZYMEWORKS WKN: A3DSSN ISIN: US98985Y1082 Forum: Aktien User: Summer.76

https://beststocks.com/title-zymeworks-inc-announces-termination-agr/

Zymeworks GAAP EPS of -$0.76 misses by $0.27, revenue of $7M misses by $9.97M https://seekingalpha.com/news/4001325-zymeworks-gaap-eps-of-0_76-misses-0_27-revenue-of-7m-misses-9_97m

Zymeworks Provides Corporate Update And Reports Second Quarter 2023 Financial Results https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-provides-corporate-update-and-reports-second-quarter-0

Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes https://www.globenewswire.com/news-release/2023/06/26/2694431/0/en/Zymeworks-Set-to-Join-Russell-3000-Russell-2000-and-Russell-Microcap-Indexes.html

https://www.businesswire.com/news/home/20230607005361/en/At-BIO-2023-Canada-Showcases-Multiple-Strengths-as-a-Biopharma-Powerhouse

https://www.drugtargetreview.com/article/110093/breakthrough-drug-candidates-and-cancer-treatment-innovations/

🎈

https://www.globenewswire.com/news-release/2023/05/18/2671878/0/en/Zymeworks-Announces-Departure-of-Neil-Klompas-President-and-Chief-Operating-Officer.html

Zymeworks Provides Corporate Update And Reports First Quarter 2023 Financial Results https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-provides-corporate-update-and-reports-first-quarter-0

Zymeworks, Jazz in pact over cancer antibody zanidatamab https://seekingalpha.com/news/3960469-zymeworks-jazz-pact-cancer-antibody-zanidatamab • Zymeworks (ZYME) will transfer some assets, contracts, and employees related to the development of its oncology antibody zanidatamab to Jazz Pharmaceuticals (NASDAQ:JAZZ) to speed up its development. • The two companies have inked a stock and asset purchase agreement to facilitate the arrangement. • Jazz (JAZZ) will be solely responsible for all development and commercial activities of zanidatamab in the US, Europe, and Japan, and other areas except for the Asia/Pacific region. Zymeworks is also partnered with Beigene (BGNE) on the asset. The Chinese pharma has rights to zanidatamab in the Asia/Pacific region. • The deal is expected to close in May. • The two companies first signed a collaboration agreement on zanidatamab in October 2022. Zymeworks (ZYME) received a $50M upfront payment and is eligible for up to $1.76B total including potential milestone payments.

https://www.globenewswire.com/news-release/2023/04/18/2649554/0/en/Zymeworks-Presents-New-Data-from-Multiple-Preclinical-and-Clinical-Development-Programs-at-the-2023-American-Association-for-Cancer-Research-Annual-Meeting.html

Zymeworks: Exciting Short Squeeze Candidate With Large Cash Holdings https://seekingalpha.com/article/4593080-zymeworks-exciting-short-squeeze-candidate-with-large-cash-holdings Summary • Zymeworks has an enterprise value approaching zero, as milestone drug development payments were paid to the company in 2022. • A significant pipeline, with partners helping to finance drug trials, is worthy of consideration. • Numerous short sellers may be trapped on overly aggressive downside bets. Short covering could spike the share quote later this year. • My momentum quant-sort formulas are now suggesting ZYME is primed to rise in the coming months. ...

https://seekingalpha.com/news/3949515-zymeworks--buy-at-wells-fargo-royalty-streams-future-milestones Zymeworks a buy at Wells Fargo on royalty streams, future milestones • Wells Fargo said that Zymeworks (NASDAQ:ZYME) is a buy citing the biotech's potential royalty streams and milestones from its lead oncology candidate. • The firm has a $12 price target (~41% upside based on Monday's close). • Derek Archila wrote that royalty streams from Jazz Pharmaceuticals (JAZZ) "offer nice floor value for the stock." Those streams are related to the bispecific antibody zanidatamab in late-stage development for various cancers. • The analyst gives a 75% probability of success for zanidatamab in biliary tract cancers with royalties coming in beginning in 2025. • Although late-stage data on zanidatamab for gastric esophageal adenocarcinoma isn't expected from Jazz (JAZZ) until H2 2024, Archila is optimistic and added that the biologics' royalty and milestone streams could add as much as $10/share. • Zymeworks (ZYME) is also partnered with BeiGene (BGNE) on zanidatamab.

https://kalkinemedia.com/us/amp/business-news/pharma/brief-zymeworks-inc-on-march-17-zymeworks-bc-inc-a-unit-of-co-and-daiichi-sankyo-entered-into-a-termination-and-license-agreement-dated-sept-26-2016

Zymeworks Q4 Adj. EPS $4.71 Misses $4.84 Estimate, Sales $402.49M Beat $371.30M Estimate https://www.benzinga.com/news/earnings/23/03/31246389/zymeworks-q4-eps-4-65-misses-4-84-estimate-sales-402-49m-beat-371-30m-estimate

Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results https://www.businesswire.com/news/home/20230307005535/en/Zymeworks-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results